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Expression of the proteolysis-inducing factor core peptide mRNA
is upregulated in both tumour and adjacent normal tissue in
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Gastro-oesophageal cancer is associated with a high incidence of cachexia. Proteolysis-inducing factor (PIF) has been identified as a
possible cachectic factor and studies suggest that PIF is produced exclusively by tumour cells. We investigated PIF core peptide (PIF-
CP) mRNA expression in tumour and benign tissue from patients with gastro-oesophageal cancer and in gastro-oesophageal biopsies
for healthy volunteers. Tumour tissue and adjacent benign tissue were collected from patients with gastric and oesophageal cancer
(n¼ 46) and from benign tissue only in healthy controls (n¼ 11). Expression of PIF-CP mRNA was quantified by real-time PCR.
Clinical and pathological information along with nutritional status was collected prospectively. In the cancer patients, PIF-CP mRNA
was detected in 27 (59%) tumour samples and 31 (67%) adjacent benign tissue samples. Four (36%) gastro-oesophageal biopsies
from healthy controls also expressed PIF-CP mRNA. Expression was higher in tumour tissue (P¼ 0.031) and benign tissue
(P¼ 0.022) from cancer patients compared with healthy controls. In the cancer patients, tumour and adjacent benign tissue PIF-CP
mRNA concentrations were correlated with each other (Po0.0001, r¼ 0.73) but did not correlate with weight loss or prognosis.
Although PIF-CP mRNA expression is upregulated in both tumour and adjacent normal tissue in gastro-oesophageal malignancy,
expression does not relate to prognosis or cachexia. Post-translational modification of PIF may be a key step in determining the
biological role of PIF in the patient with advanced cancer and cachexia.
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Although cachexia is a major cause of morbidity and mortality
among cancer patients, the mechanisms remain unclear. Proteo-
lysis-inducing factor (PIF) has been identified as a possible
cachectic factor (Todorov et al, 1996). Initially isolated from a
murine tumour model (MAC16), a human homologue of PIF was
subsequently identified in human urine from weight losing cancer
patients (Todorov et al, 1996; Cariuk et al, 1997; Wigmore et al,
2000). Proteolysis-inducing factor has been named as such because
it has been shown to induce skeletal muscle proteolysis both in
vitro and in vivo (Lorite et al, 1997, 2001; Watchorn et al, 2001).
The molecule demonstrates a high degree of glycosylation,
consisting of a peptide core of 4 kDa and carbohydrate residues
contributing to the estimated total molecular size of 24 kDa
(Todorov et al, 1997). The glycosylation appears essential for its
proteolytic activities, as neither the peptide core alone nor de-
glycosylated native PIF has any effect on weight loss in mice
(Todorov et al, 1996).
In hepatocytes, glycosylated PIF has been shown to stimulate
production of the cytokines interleukin-6 (IL-6) and IL-8 and the
acute-phase protein C-reactive protein (CRP) via induction of
transcription factors NF-kB and STAT3 (Watchorn et al, 2001).
Therefore, PIF may contribute to the inflammatory state observed
in conjunction with cancer cachexia in addition to its proteolytic
function, and could conceivably also play a role in the generation
of a proinflammatory state outwith the context of cancer.
Some gastrointestinal cancers and cancer cell lines have been
shown to produce glycosylated PIF protein (Cabal-Manzano et al,
2001). Glycosylated PIF has been detected within tumour cells by
immunohistochemistry and in the urine of the same subjects by
Western blot. The presence of glycosylated PIF in tumour cells was
also associated with increased weight loss among these patients.
Proteolysis-inducing factor has also been identified from the
human melanoma cell line (G361) (Todorov et al, 1999) and the
pancreatic cell line (MIA PaCa2) (unpublished data).
Human-derived PIF has been designated human cachexia-
associated protein (HCAP) by early identification of the human
gene sequence (GenBank accession number AR053250) and patent
(US 5834192) (Akerblom and Murry, 1998) and later by a group,
which investigated its expression in prostate cancer patients
(Wang et al, 2003). mRNA of HCAP was detected in 13 out of 15
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radical prostatectomy specimens and seven out of nine bone
metastases, but was not detectable in normal prostate or in any
adjacent non-malignant prostate tissue from prostatectomy
samples. In situ hybridisation confirmed that HCAP mRNA was
only detectable in cancer cells and not in surrounding stromal cells
or benign prostate tissue. Expression of HCAP mRNA was also
detected from prostate cancer cell lines. When two of these cell
lines (PC-3M and LuCaP35) were implanted into mice, there was a
strong correlation between HCAP mRNA expression from the
cancer cells and weight loss among the mice (Wang et al, 2003).
A BLAST search of the human genome using the PIF core
peptide (PIF-CP) cDNA sequence (GenBank accession number
AY590150) identified three products that arise from the single gene
locus on 12q3.1; dermcidin (DCD), neuronal survival-promoting
peptide, and a candidate breast cancer oncogene. Dermcidin is a
novel peptide that was identified from human sweat and was
shown to possess antimicrobial properties (Schittek et al, 2001).
Unlike the PIF molecule, DCD appears to be unglycosylated.
Dermcidin mRNA was detected in normal skin, benign naevi, and
malignant melanoma cells by RT–PCR. Screening of adult and
fetal tissue panels did not identify DCD mRNA in any other tissue.
The authors therefore concluded that DCD was exclusive to skin
and associated appendages.
Another PIF homologue has been identified following its
isolation from the culture medium of neuronal cells grown under
oxidative stress (Cunninghan et al, 1998). In vivo studies suggest
that this protein confers survival benefits to hypoxic neuronal cells
and the molecule has been termed neuronal diffusible survival-
promoting peptide.
The third peptide, which has been mapped to the PIF gene locus,
was identified using SAGE in breast cancer tissue (Porter et al,
2003). The gene was expressed only in a subset of invasive breast
carcinomas and their lymph node metastases. In situ hybridisation
studies located the mRNA to cancer cells only with no expression
found within stromal cells. Northern blot analysis of 75 human
adult and fetal tissues detected RNA expression only in the pons
and paracentral gyrus of the brain. The protein was identified in
10% of invasive breast cancers, two out of 64 pancreatic cancers,
and normal sweat glands. Receptors were found in the brain and
on tumour cells that were producing the protein, suggesting an
autocrine/paracrine mode of action. When the cDNA sequence was
introduced into a breast cancer cell line (21NT), these cells had
accelerated growth and were more resistant to oxidative stress and
hypoglycaemia. The authors have suggested that this gene may
function as an oncogene in breast cancer with survival-promoting
properties.
More recently, a group of investigators probed a panel of normal
human tissue cDNA for PIF-CP using real-time PCR and found
absent or very low levels of expression (Monitto et al, 2004). In an
analysis of unpaired breast tissue samples, minimal PIF expression
in normal breast tissue was detected. However, significantly
elevated PIF expression within breast tumours was observed. Mice
implanted with tumours transfected with a PIF vector were found
to produce increased levels of PIF mRNA and protein but the
protein was not glycosylated and these mice did not develop
wasting. However, the tumours from these mice were significantly
larger than controls, supporting a previous hypothesis that PIF
may confer cell survival properties (Cunningham et al, 1998).
PIF mRNA and protein are not expressed in most normal tissues
and are overexpressed by certain tumours. We investigated the
expression of the PIF-CP gene in paired tissue samples from
patients with gastric or oesophageal tumours and compared levels
of expression between tumour tissue and adjacent non-neoplastic
tissue using the PIF mRNA sequence that our group had
previously cloned (GenBank accession number AY590150). We
also compared levels of gene expression with nutritional status and
investigated the possible survival-promoting role of the PIF-CP
gene on prognosis and survival among the patient cohort.
MATERIALS AND METHODS
Study patients
All patients diagnosed with gastric or oesophageal cancer between
June 2002 and March 2004 within Lothian and Borders regions
were invited to take part in the study. Patients who were not
suitable for surgical resection were excluded. Patients provided
written informed consent and the study received ethical permis-
sion from the Lothian Research Ethics Committee. Clinical
information was collected prospectively. Patients were staged
according to the International Union Against Cancer (UICC)
(Sobin and Wittekind, 2003), and final histopathological stage
(pTNM) was used in all cases. Tumours around the oesophago-
gastric junction were classified according to Siewert and those
classified as type I and II were classified as oesophageal tumours,
and type III as gastric cancers (Siewert and Stein, 1998). Full
clinical and pathological information was recorded for each
patient, including treatment modality. Patients provided urine
samples at the time of recruitment and whole blood was collected
at the same time. Duration of survival, defined as time from
histological diagnosis to death, was recorded for all patients and all
deaths were disease related.
Gastric or oesophageal biopsies were collected from 11
healthy volunteers at the time of endoscopic examination. These
patients were undergoing endoscopic investigation of gastro-
intestinal symptoms. In all instances, both the macroscopic
and microscopic assessments were considered normal. Those
patients with abnormal findings were excluded as healthy
controls. The tissue was sampled with biopsy forceps and the
histological appearances were confirmed as normal by a consultant
pathologist (HG).
Nutritional assessment
Nutritional assessment including calculation of body mass index
from the patients’ weight and height and measurement of mid-arm
circumference (MAC) and triceps skinfold thickness (triceps) was
performed as described previously (Wigmore et al, 2000). Mid-arm
muscle circumference (AMC) was calculated by means of Jelliffe’s
(1966)equation. Premorbid patient weight was recalled by the
patient and confirmed where possible from the medical notes.
Anthropometry measurements were normalised using standar-
dised reference tables (Bishop et al, 1981).
Tissue collection
Tissue was obtained from patients at the time of surgical resection.
A section of tumour tissue and a sample of benign mucosa from
the same organ were collected from each patient. A single
consultant pathologist (HG) analysed tissue sections to confirm
the presence of malignant cells in the tumour samples and the
absence of malignant cells within the benign samples. Tissue
samples were snap-frozen in liquid nitrogen before storage at
801C until further analysis. The average time from tissue
collection to freezing was 15 min (range 10– 25 min). Tumour
tissue and benign tissue were collected from the same patient in all
cases. Tissue biopsies collected from healthy controls were snap-
frozen within 1 min of collection.
Quantitative polymerase chain reaction (Q-RT–PCR)
RNA isolation and reverse transcription Total RNA was isolated
from tissue samples using the RNAeasy kit (Qiagen Inc., Crawley,
UK). RNA quality and integrity was assessed using an Agilent 2100
bioanalyser (Agilent Technologies Ltd, Chesire, UK) in five
samples. For the remaining samples, purity and concentration
were determined using spectrophotometry (Ultrospec 2000,
Pharmacia Biotech, Bucks, UK). RNA samples were treated with
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DNase (Qiagen Inc., UK) and all RNA samples were checked for
genomic DNA contamination before reverse transcription using
standard PCR for cytochrome b.
Reverse transcription was performed once DNA contamination
had been excluded. The reaction mixture included RNA (1mg in
10 ml diethyl-pyrocarbonate (DEPC)-treated water), 4 ml MgCl2
(25 mM), 2 ml 10 reverse transcriptase buffer, 2 ml dNTPs
(10 mM), 1 ml random hexamers (500 mg ml1), 1.5ml AMV reverse
transcriptase (10 U ml1), and 0.5 ml recombinant RNase inhibitor
(40 U ml1) (all reagents Promega, Southampton, UK). Reverse
transcription was performed at 421C for 60 min followed by 951C
for 5 min.
Real-time PCR Quantitative PCR was performed using the ABI
PRISM 770 real-time Sequence Detection System (Applied
Biosystems, Warrington, UK). Reactions were performed in 50 ml
total volume, consisting of 25 ml Taqman universal PCR master-
mix (UNG  2), 14 ml primer/probe mix, 2.5ml ribosomal 18S
primer/probe mix (all reagents Applied Biosystems, Warrington,
UK), 3.5 ml DEPC-treated water, and 5 ml cDNA. The reaction
conditions were 2 min at 501C, 10 min at 951C, and 40 cycles with
15 s at 951C and 1 min at 601C. The primers and probes were
designed using Primer Expresss software based on our previously
registered sequence for PIF (GenBank accession number
AY590150) and the sequences were checked for compatibility by
Applied Biosystems (Warrington, UK). The primers were 50-
CAAAAGGAAAATGCAGGTGAAGA, 50-TGGAAAAAGGCCTAGA
CGGAG, and the probe 50FAM-ACAGGCACCAAAGCCAAGGAAG
CA-TAMRA.
Quantification of gene expression was calculated using the
comparative (DDCT) method, where samples were compared with
the positive control (Bustin, 2000). Human ribosomal 18S was used
as the internal control for all PCR reactions. The values generated
for the gene of interest (PIF-CP) were normalised to the internal
control as follows: the average threshold cycle numbers for PIF (CT
FAM) and for 18S (CT VIC) were calculated for each sample and
the mean VIC CT values were subtracted from the mean FAM CT
values (FAM CTVIC CT¼DCT). Samples that generated cycle
numbers greater than 23 for the internal control (18S; VIC) were
considered too dilute for accurate analysis and these samples were
repeated.
The level of gene expression within each sample was then
expressed as a percentage of the total level of gene expression by
the positive control (MIA PaCa2). Expression of PIF-CP by the
positive control was also initially normalised to the internal
control. Then, DDCT was calculated by subtracting the DCT
value of the positive control sample from the DCT value for
each sample (i.e. DCT sampleDCT control¼DDCT). The relative
level of expression, normalised to the endogenous control and
relative to the positive control, was then calculated by the formula
2DDCT : The level of gene expression of the positive control was
assigned an arbitrary expression value of 1 and levels of gene
expression in the samples were expressed as percentages of the
positive control level.
Each sample was analysed in duplicate. The variability between
duplicates was between 0 and 4.8%. To investigate inter-plate
variability, between five and 10 randomly selected samples were
repeated on different test plates and serial dilutions of the positive
control cDNA were also performed. Inter-plate reproducibility was
between 3.7 and 15.5%.
Positive control Previous work undertaken by our group has
identified the pancreatic cancer cell line MIA PaCa2 to consistently
produce PIF-CP mRNA. This cell line was, therefore, used as
positive control for real-time PCR analysis. Total RNA was
collected from cultured cells by the Trizol extraction method
(Invitrogen, Renfrew, UK) before undergoing reverse transcription
as described above.
Acute-phase proteins
C-reactive protein was determined using an immunoturbidimetric
assay (Abbott TDX, Abbott Laboratories, Maidenhead, UK). A
level above 10 mg l1 represents the presence of an acute-phase
response. The remaining acute-phase proteins (transferrin, hap-
toglobin, and a1-antichymotrypsin) were determined by enzyme-
linked immunosorbent assay as described previously (Wigmore
et al, 2002).
Statistical analysis
Differences in levels of PIF-CP mRNA expression between different
tissue types and PIF urinary expression were analysed by the
Mann– Whitney U-test. Survival differences were tested by the log-
rank test. Comparisons between tumour tissue PIF-CP gene
expression and benign tissue expression were tested by linear
regression analysis following natural logarithmic transformation of
the data. Stage was analysed by the w2 test. Probabilities p0.05
were considered significant.
RESULTS
Study patients
Patient demographics are shown in Table 1. Forty-six patients were
recruited to the study, the median age was 65 years (inter-quartile
range 58– 75) and 32 (70%) of the patients were men. The primary
tumour sites were oesophageal (n¼ 22, 48%), gastric (n¼ 15,
33%), and those arising from the gastro-oesophageal junction
Table 1 Patient demographics (n¼ 46)
Number (%)
Age (years) 65 (58–75)
Sex
Male 32 (70)
Female 14 (30)
Tumour site
Oesophageal 22 (48)
Oesophago-gastric junction 9 (20)
Gastric 15 (33)
Histology
Adenocarcinoma 43 (94)
Squamous cell carcinoma 3 (6)
Grade
Well differentiated 4 (9)
Moderately differentiated 20 (44)
Poorly differentiated 22 (48)
UICC stage
1 14 (30)
2 12 (26)
3 15 (33)
4 5 (11)
Treatment undertaken
Oesophagectomy alone 20 (43)
Gastrectomy alone 15 (33)
Preoperative chemotherapy followed by surgery 11 (24)
Status
Alive 35 (76)
Dead 11 (24)
Values are median (inter-quartile range). UICC¼ International Union Against Cancer.
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(n¼ 9, 20%). Histological confirmation of disease was obtained in
all cases and the predominant histological subtype was adeno-
carcinoma (94%). All patients underwent surgical resection and 11
(24%) of these received preoperative chemotherapy. At the end of
the study, 11 (24%) patients had died.
All the control patients were considered healthy and all were
weight stable. These patients underwent endoscopy as an elective
investigation and in all instances the result of the procedure was
normal, including both macroscopic and microscopic assessment.
Helicobacter pylori was not detected in any of these tissue samples.
Expression of PIF-CP mRNA in tissues
Healthy controls mRNA of PIF-CP was detected in gastro-
oesophageal biopsy tissue from four (36%) healthy controls. Of
these positive tissue samples, three were gastric biopsies, and one
was oesophageal tissue. Although PIF-CP mRNA levels were
detectable, the levels of expression were significantly lower when
compared with levels of expression in tumour tissue (P¼ 0.031,
Mann– Whitney U-test) and adjacent benign tissue (P¼ 0.022)
taken from cancer patients (Figure 1).
Study patients PIF-CP mRNA was detected in 27 (59%) tumour
samples and 31 (67%) adjacent benign tissue samples. In 24 (52%)
patients, PIF mRNA was detected in both the tumour tissue and
adjacent benign tissue collected from the same patient (Table 2).
There was a strong correlation between paired mRNA concentra-
tions in tumour tissue and mRNA concentrations in adjacent
benign tissue (Po0.0001, r¼ 0.73; linear regression) (Figure 2).
However, there was no difference in the level of gene expression
between tumour tissue and adjacent benign tissue from the cancer
patients (P¼ 0.51, Mann–Whitney U-test) (Figure 1). In 12 (26%)
patients, PIF-CP mRNA was not detected in either the tumour or
adjacent benign tissue. For the remaining 10 patients, PIF-CP
mRNA was detected in either tumour tissue only (n¼ 3) or
adjacent benign tissue only (n¼ 7). There was no difference in the
level of gene expression between patients who received preopera-
tive chemotherapy and those who did not (tumour tissue, P¼ 0.58;
adjacent benign tissue, P¼ 0.72: Mann– Whitney U-test).
Tissue PIF-CP mRNA expression and nutritional status
Tumour tissue PIF-CP mRNA did not correlate with weight loss
(P¼ 0.37; linear regression), MAC (P¼ 0.10), triceps skinfold
thickness (P¼ 0.37), or AMC (P¼ 0.14). Similarly, benign tissue
mRNA concentrations did not correlate with weight loss (P¼ 0.84)
or any anthropometric measurements. Patients in whom PIF-CP
mRNA was measurable in both tumour and adjacent benign
tissues did not have adverse nutritional status when compared
with patients without detectable PIF-CP mRNA in either tissue
type (Table 3). There remained no correlation when the data were
analysed according to dysphagia scores (data not shown).
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Figure 1 A comparison of relative expression of PIF-CP mRNA in tissue
from healthy controls (normal), tumour tissue, and benign tissue collected
from cancer patients (benign). The lines represent the median value,
bars¼ inter-quartile range, error bars¼ extreme values (Mann–Whitney
U-test).
Table 2 Tissue expression of PIF-CP mRNA in paired tumour tissue and
benign tissue
Paired tumour tissue and benign tissue
expression
Benign tissue expression only
24 (52%) 7 (15%)
Tumour tissue expression only Neither tumour tissue nor benign tissue
expression
3 (7%) 12 (26%)
PIF-CP¼ proteolysis-inducing factor core peptide.
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Figure 2 Correlation between paired tumour tissue PIF-CP mRNA
concentrations and benign tissue PIF-CP mRNA concentrations
(Po0.0001, r¼ 0.73; linear regression). All values underwent natural
logarithmic transformation.
Table 3 Tissue PIF-CP mRNA expression and nutritional variables
PIF-CP mRNA
detected in both
tumour tissue and
benign tissue
(n¼ 24)
PIF-CP mRNA
not detectable in
either tumour
tissue or benign
tissue (n¼12) P value
Weight loss (%) 3.3 (0.4–9.5) 5.3 (0–12.2) 0.93
MAC (percentile group) 10–25 (5–50) 10–25 (5–50) 0.96
Triceps (percentile group) 25–50 (10–50) 25–50 (25–50) 0.37
AMC (percentile group) 10–25 (5–50) 25–50 (5–50) 0.96
Nutritional variables were similar between patients in whom PIF-CP mRNA was
measurable in both tumour tissue and benign tissue and patients who had no
detectable mRNA (Mann–Whitney U-test). Absolute values were normalised into
percentile groups before analysis. Values are median (inter-quartile range). PIF-
CP¼ proteolysis-inducing factor core peptide, MAC¼mid-arm circumference,
triceps¼ triceps skinfold thickness, AMC¼ arm muscle circumference.
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Tissue PIF-CP mRNA expression and systemic
inflammation
Nine (20%) patients had an elevated serum CRP (410 mg l1),
which may be used as a surrogate marker of systemic inflamma-
tion. There was no association between levels of PIF-CP mRNA in
either tumour tissue (P¼ 0.89) or adjacent benign tissue (P¼ 0.81)
and elevated serum acute-phase protein concentrations (Mann–
Whitney U-test).
Tissue PIF-CP mRNA expression and prognosis
PIF-CP mRNA in either tumour tissue (P¼ 0.64) or benign tissue
(P¼ 0.51) was not associated with adverse prognosis (Mann–
Whitney U-test). Similarly, those patients with detectable mRNA in
both tumour and benign tissue did not have adverse survival
compared with patients with no detectable PIF-CP gene in either
tissue type (P¼ 0.79; w2 analysis).
We found no association between mRNA levels and age, sex,
tumour position, histology, degree of differentiation, or stage (data
not shown).
DISCUSSION
Previous studies have suggested that PIF-CP mRNA is absent or
expressed at only minimal levels in normal human tissues and
found at significantly elevated levels in some tumours and various
cancer cell lines. However, we have detected PIF-CP mRNA in
benign tissue in the majority of patients with gastro-oesophageal
cancer, and these levels are equivalent to levels detected within
adjacent tumour tissues. In addition, we detected PIF-CP mRNA in
biopsy tissue from healthy controls, although at significantly lower
levels of expression. In a previous study, PIF-CP (HCAP) mRNA
appeared to be limited to cancer cells and their metastases (Wang
et al, 2003). Our data suggest that PIF-CP gene expression is not
limited to neoplastic tissue and that the PIF-CP gene may also be
active in normal tissues. Furthermore, the level of gene expression
appears to be similar in tumour tissue and adjacent benign tissue.
Therefore, in some individuals with cancer, there may be
upregulation of the PIF-CP gene not only in tumour tissue but
also within the whole organ or even in distant tissues.
The relevance of PIF-CP gene upregulation remains obscure.
Although PIF-CP has been identified as a putative cell survival
factor we found no association between gene expression and
prognosis, stage, or grade of tumour. Therefore, the present study
is unable to confirm a tumour survival-promoting role for this
gene in our study. Mice implanted with a tumour carrying the PIF-
CP gene demonstrated increased rate of tumour growth compared
with controls (Monitto et al, 2004). The present study did not
evaluate tumour volume, but we did not identify any differences in
tumour stage or grade between patients with elevated mRNA levels
and those with undetectable mRNA levels.
Tissue PIF-CP mRNA expression was not associated with weight
loss or any adverse nutritional variable. Previously, we have found
an association between weight loss and urinary PIF (Todorov et al,
1996; Cariuk et al, 1997; Wigmore et al, 2000). In those studies, we
detected the glycosylated PIF protein, whereas in this study, we
have measured mRNA for the core peptide and so this finding is
perhaps unsurprising. Only a small fraction of the total peptide
core would be expected to be glycosylated, and as PIF is only
present at 1 part in 108 of the total protein, expression of the
peptide core would not be expected to be rate limiting for PIF
formation, rather the expression of the glycosidases, their rate of
catalysis, and substrate availability (Todorov et al, 1996). Whether
variation in glycosylation of PIF occurs and whether this
influences biological activity is unknown. Antibodies raised
against the core peptide do not reliably detect urinary PIF.
Systemic inflammation was identified in 20% of patients and
was not associated with PIF core tissue mRNA concentrations. In
vitro work has demonstrated that hepatocytes produce increased
levels of IL-6, IL-8, and CRP in response to PIF stimulation
(Watchorn et al, 2001). This is thought to be mediated through
transcription factors NF-kB and STAT3. Proteolysis-inducing
factor may play only a minor role in the complex interaction
between proinflammatory mediators and a direct relationship
between PIF and acute-phase proteins may not be identified
outwith the in vitro cell model.
It has been suggested that PIF is an important protein during
embryological development and becomes quiescent during adult
life (Watchorn et al, 2001). Neoplastic transformation would then
allow the re-expression of the gene in adulthood (similar to
carcinoembryonic antigen). We have found PIF-CP mRNA
expression in normal healthy tissue albeit at reduced levels
compared with tumour tissue and benign tissue from cancer
patients and so this explanation is perhaps implausible for PIF-CP
but may be important in re-expression of the glycosyltransferases.
It is also important to consider that real-time PCR is an exquisitely
sensitive technique and that what we are detecting in some
patients, although elevated, may have little or no functional
significance as it may not be translated into protein.
It is possible that the gene for the PIF-CP may confer a survival
advantage to a tumour, promoting tumour growth and spread,
although this study was unable to confirm this. Alternatively, the
PIF-CP gene may be expressed to some degree in all tissue types
and its diverse functions are due to post-transcriptional and post-
translational modifications. The high degree of glycosylation of the
PIF molecule may be due to aberrant glycosylation by tumour cells
and this glycosylation may confer the proteolytic activity
associated with PIF (Todorov et al, 1997). This aberrantly
processed molecule could not be distinguished from any conven-
tional versions by determination of the mRNA expression.
PIF-CP mRNA is expressed in healthy tissue and is found at
significantly elevated levels within tumour tissue and adjacent
benign tissue. However, measuring mRNA expression is unreliable
as an indicator of glycosylated PIF protein expression and
therefore has limited value both as a diagnostic and prognostic
test. Attention needs to be directed at developing robust and
reproducible quantitative assessments of glycosylated PIF protein.
Such tests need to be able to identify PIF in complex matrices such
as plasma or urine and must be able to identify glycosylation
variants of the moiety. Similarly, such tests need to distinguish
between different proteins carrying identical glycosylation motifs.
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